News articles about Pluristem Therapeutics (NASDAQ:PSTI) have trended somewhat positive on Friday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pluristem Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.5740852085221 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Pluristem Therapeutics Inc. (PSTI) folded -4.41% below from its SMA-50 – Street Observer (press release) (streetobserver.com)
- Checking in on Pluristem Therapeutics Inc (PSTI)’s Signals – Berry Recorder (berryrecorder.com)
- Health Care Sector Update for 08/16/2017: PSTI,IDXG,JAGX – Nasdaq (nasdaq.com)
- ABIO To Report Data In Q1; IOVA Fired Up, PMD In Iowa, VRX All Cleared – Markets Insider (markets.businessinsider.com)
- Here’s A Quick Technical Analysis Of Pluristem Therapeutics Inc. (PSTI) – StockNewsGazette (stocknewsgazette.com)
PSTI has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $3.50 price target on shares of Pluristem Therapeutics in a research note on Friday, May 5th. Maxim Group reissued a “hold” rating on shares of Pluristem Therapeutics in a research note on Thursday, May 4th.
Pluristem Therapeutics (NASDAQ PSTI) traded up 1.69% during trading on Friday, hitting $1.20. 185,483 shares of the company traded hands. Pluristem Therapeutics has a 12-month low of $1.04 and a 12-month high of $1.85. The stock has a 50-day moving average price of $1.19 and a 200-day moving average price of $1.27. The firm’s market capitalization is $115.60 million.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Pluristem Therapeutics (NASDAQ:PSTI) Stock Price” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/08/18/pluristem-therapeutics-nasdaqpsti-getting-somewhat-positive-media-coverage-report-finds-updated.html.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
What are top analysts saying about Pluristem Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pluristem Therapeutics Inc. and related companies.